Martins Eduardo Bruno — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Martins Eduardo Bruno is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $95K.
Profile
Eduardo Bruno Martins is the Chief Medical Officer at Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing selective fatty acid synthase inhibitors. He has been involved in the company's efforts to address diseases related to lipid metabolism, particularly through the drug candidate denifanstat.
Eduardo Bruno Martins is the Chief Medical Officer at Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing selective fatty acid synthase inhibitors. He has been involved in the company's efforts to address diseases related to lipid metabolism, particularly through the drug candidate denifanstat.…
Has Martins Eduardo Bruno been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($95K) across all tracked filings.
Where can I see all of Martins Eduardo Bruno's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
